|
業務類別
|
Biotechnology |
|
業務概覽
|
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus;and Tripledemic. |
| 公司地址
| 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021 |
| 電話號碼
| +1 713 913-5608 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.decoytx.com |
| 員工數量
| 11 |
| Mr. Mark J. Rosenblum |
Executive Vice President, Finance, Chief Financial Officer and Principal Accounting Officer |
美元 330.00K |
31/03/2026 |
| Mr. Frederick E. Pierce |
Director and Chief Executive Officer |
-- |
31/03/2026 |
| Mr. Peter Klaus Marschel, M.B.A. |
Chief Business Officer |
-- |
13/11/2025 |
| Dr. Barbara Louise Hibner, PhD |
Chief Scientific Officer |
-- |
13/11/2025 |
|
|
| Mr. Jonathan I. Lieber, M.B.A. |
Independent Director |
31/03/2026 |
| Mr. Arnold C. Hanish |
Independent Director |
31/03/2026 |
| Dr. William K. McVicar, PhD |
Chairman of the Board |
31/03/2026 |
| Mr. Frederick E. Pierce |
Director and Chief Executive Officer |
31/03/2026 |
| Dr. Paul Lammers, M. Sc.,M.D. |
Lead Independent Director |
31/03/2026 |
| Ms. Tess Burleson |
Independent Director |
31/03/2026 |
| Mr. David J. Arthur |
Director |
31/03/2026 |
|
|
|
|
